Ab­b­Vie bets $48M up­front for ear­ly-stage an­ti­body tar­get­ing chron­ic in­flam­ma­tion

Ab­b­Vie is mak­ing good on its plans to search for new mech­a­nisms of ac­tion, this time with French biotech OSE Im­munother­a­peu­tics for a mon­o­clon­al an­ti­body tar­get­ing in­flam­ma­tion.

Ab­b­Vie will pay $48 mil­lion up­front to OSE for an ex­clu­sive glob­al li­cense to de­vel­op, man­u­fac­ture and com­mer­cial­ize the an­ti­body, dubbed OSE-230. OSE is el­i­gi­ble for an­oth­er $665 mil­lion in mile­stones as well as tiered roy­al­ties on glob­al net sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER